Bioventus Q4 2025 Earnings Call Summary: Strategic Performance, 2026 Objectives and Investment Framework, and Operational Risks.

Bioventus Inc. reported Q4 2025 earnings with 10% organic revenue growth, attributed to commercial execution and market shifts. Pain Treatments grew due to volume increases in Duralane, while Restorative Therapies achieved its highest growth in seven years. Profitability expanded 490 basis points. The company plans to invest $13 million in key drivers, including Peripheral Nerve Stimulation and Platelet-Rich Plasma, expecting a minimum of 200 basis points of growth in 2026.